MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1507574

Медицинская библиотека · The New England journal of medicine · 2015

Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.

Morillo Carlos A, Marin-Neto Jose Antonio, Avezum Alvaro, Sosa-Estani Sergio, Rassi Anis, Rosas Fernando, Villena Erick, Quiroz Roberto, Bonilla Rina, Britto Constança, Guhl Felipe, Velazquez Elsa, Bonilla Laura, Meeks Brandi, Rao-Melacini Purnima, Pogue Janice, Mattos Antonio, Lazdins Janis, Rassi Anis, Connolly Stuart J, Yusuf Salim, BENEFIT Investigators

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.

METHODS

We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis was the first event of any of the components of the composite outcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or other thromboembolic event.

RESULTS

The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and in 414 (29.1%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.07; P=0.31). At baseline, a polymerase-chain-reaction (PCR) assay was performed on blood samples obtained from 1896 patients; 60.5% had positive results for Trypanosoma cruzi on PCR. The rates of conversion to negative PCR results (PCR conversion) were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, respectively, at 2 years, and 46.7% and 33.1%, respectively, at 5 years or more (P<0.001 for all comparisons). The effect of treatment on PCR conversion varied according to geographic region: in Brazil, the odds ratio for PCR conversion was 3.03 (95% CI, 2.12 to 4.34) at 2 years and 1.87 (95% CI, 1.33 to 2.63) at 5 or more years; in Colombia and El Salvador, the odds ratio was 1.33 (95% CI, 0.90 to 1.98) at 2 years and 0.96 (95% CI, 0.63 to 1.45) at 5 or more years; and in Argentina and Bolivia, the odds ratio was 2.63 (95% CI, 1.89 to 3.66) at 2 years and 2.79 (95% CI, 1.99 to 3.92) at 5 or more years (P<0.001 for interaction). However, the rates of PCR conversion did not correspond to effects on clinical outcome (P=0.16 for interaction).

CONCLUSIONS

Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up. (Funded by the Population Health Research Institute and others; ClinicalTrials.gov number, NCT00123916; Current Controlled Trials number, ISRCTN13967269.).

Для цитирования: Morillo Carlos A, Marin-Neto Jose Antonio, Avezum Alvaro, Sosa-Estani Sergio, Rassi Anis, Rosas Fernando, Villena Erick, Quiroz Roberto, Bonilla Rina, Britto Constança, Guhl Felipe, Velazquez Elsa, Bonilla Laura, Meeks Brandi, Rao-Melacini Purnima, Pogue Janice, Mattos Antonio, Lazdins Janis, Rassi Anis, Connolly Stuart J, Yusuf Salim, BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.. The New England journal of medicine. 2015. DOI: 10.1056/nejmoa1507574.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.